Resveratrol decreases the insoluble Aβ1–42 level in hippocampus and protects the integrity of the blood–brain barrier in AD rats

Zhao, Haifeng; Li, N.; Wang, Q.; Cheng, Xuejiao; Li, X.M.; Liu, T.T.

doi:10.1016/j.neuroscience.2015.10.006

Cited by 121 publications

(78 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Resveratrol, a polyphenol present in red wine and peanuts, is also being studied in AD due in part to its antioxidant properties, potential to down-regulate various inflammatory markers like TNF-α, maintenance of BBB integrity, and activation of Sirtuin-1 [91]. A recent Phase 2 RCT of resveratrol in patients with mild-to-moderate AD examined the safety of resveratrol over 52 weeks and its effect on biomarkers [92].…”

Section: Antioxidantsmentioning

confidence: 99%

Targeting neuroinflammation in Alzheimer’s disease: evidence for NSAIDs and novel therapeutics

Deardorff

Grossberg

2016

Expert Review of Neurotherapeutics

View full text Add to dashboard Cite

There is an increasing recognition of the immune system as an important mediator in the pathogenesis of Alzheimer's disease (AD). As immune system modulators, non-steroidal anti-inflammatory drugs (NSAIDs) garnered initial enthusiasm from pre-clinical and epidemiologic studies as agents to reduce the risk of AD. Areas covered: This article will examine the evidence for the use of NSAIDs in AD by discussing the proposed mechanism of action, results from epidemiologic studies, and data from randomized controlled trials. In addition, a survey of several novel approaches to targeting inflammatory pathways currently in pre-clinical and clinical phases of development is presented. These agents primarily act to modulate microglial functioning, enhance amyloid-β phagocytosis, suppress potentially harmful pro-inflammatory responses, or enhance systemic immunity. Expert commentary: While long-term use of NSAIDs is associated with a reduced incidence of AD in epidemiologic studies, randomized controlled trials have not replicated these findings. Thus, NSAID use cannot currently be recommended either for primary prevention or treatment of AD. However, the available evidence does suggest that cognitively normal patients taking long-term courses of NSAIDs for other indications likely have a decreased risk of AD, which represents an important finding given the high prevalence of NSAID use among older adults.

show abstract

Section: Antioxidantsmentioning

confidence: 99%

Targeting neuroinflammation in Alzheimer’s disease: evidence for NSAIDs and novel therapeutics

Deardorff

Grossberg

2016

Expert Review of Neurotherapeutics

View full text Add to dashboard Cite

show abstract

“…In their study, Turner et al (2015) observed that resveratrol and its metabolites were present in plasma and the CNS and based on this observation suggest that penetration of these metabolites across the blood brain barrier occurred. As shown in mouse models resveratrol may protect the integrity of the BBB by preserving normal cerebral endothelial function and thus BBB permeability (Lin et al, 2010; Zhao et al, 2015). Resveratrol protects the BBB and also inhibits beta-amyloids accumulating in the hippocampus as demonstrated in AD rat models (Zhao et al, 2015).…”

Section: Polyphenols and Alkaloidsmentioning

confidence: 97%

“…As shown in mouse models resveratrol may protect the integrity of the BBB by preserving normal cerebral endothelial function and thus BBB permeability (Lin et al, 2010; Zhao et al, 2015). Resveratrol protects the BBB and also inhibits beta-amyloids accumulating in the hippocampus as demonstrated in AD rat models (Zhao et al, 2015). Resveratrol may also play a role in neuroprotection by inhibiting interleukin beta (IL-1β) and BV-2 murine microglial cells (Abraham and Johnson, 2009), and with its derivatives inhibiting microglial activation and reducing the production of pro-inflammatory factors (Candelario-Jalil et al, 2007; Meng et al, 2008).…”

Section: Polyphenols and Alkaloidsmentioning

confidence: 97%

The Immunomodulatory Effects of Plant Extracts and Plant Secondary Metabolites on Chronic Neuroinflammation and Cognitive Aging: A Mechanistic and Empirical Review

2017

View full text Add to dashboard Cite

Advances in healthcare have considerably improved the life expectancy of the human population over the last century and this has brought about new challenges. As we live longer the capacity for cognitive aging increases. Consequently, it has been noted that decline in cognitive performance in the elderly in domains of reasoning, problem solving skills, attention, processing speed, working memory and episodic memory is a significant societal problem. Despite the enormity of this issue there are relatively few interventions for cognitive aging. This may be due to our current state of knowledge on biological factors that underpin cognitive aging. One of the biological contributors to cognitive aging is chronic neuroinflammation. This review will provide an overview of the peripheral and central mechanisms involved in chronic neuroinflammation and how neuroinflammation may be related to age-associated cognitive decline. Plant based extracts including herbal and nutritional supplements with anti-inflammatory properties will be examined in relation to their utility in treating age-related cognitive decline. Plant based extracts in particular offer interesting pharmacological properties that may be quickly utilized to prevent cognitive aging.

show abstract

“…These include apocynin [66,67,68], baicalein [69], caffeine [70,71,109], curcumin [72,73,74], niacin [64], nicotine [64], pinocembrin [75,76,110], resveratrol [77,78,79,80,81,111], polyphenols [112], and tanshinone IIA [82,83,84]. However, the number of studies investigating the effects of these agents on neurodegeneration and cognitive performance is limited.…”

Section: Antioxidants Cognitive Decline and Blood-brain Barriermentioning

confidence: 99%

Antioxidants and Dementia Risk: Consideration through a Cerebrovascular Perspective

2016

View full text Add to dashboard Cite

A number of natural and chemical compounds that exert anti-oxidative properties are demonstrated to be beneficial for brain and cognitive function, and some are reported to reduce the risk of dementia. However, the detailed mechanisms by which those anti-oxidative compounds show positive effects on cognition and dementia are still unclear. An emerging body of evidence suggests that the integrity of the cerebrovascular blood-brain barrier (BBB) is centrally involved in the onset and progression of cognitive impairment and dementia. While recent studies revealed that some anti-oxidative agents appear to be protective against the disruption of BBB integrity and structure, few studies considered the neuroprotective effects of antioxidants in the context of cerebrovascular integrity. Therefore, in this review, we examine the mechanistic insights of antioxidants as a pleiotropic agent for cognitive impairment and dementia through a cerebrovascular axis by primarily focusing on the current available data from physiological studies. Conclusively, there is a compelling body of evidence that suggest antioxidants may prevent cognitive decline and dementia by protecting the integrity and function of BBB and, indeed, further studies are needed to directly examine these effects in addition to underlying molecular mechanisms.

show abstract

Resveratrol decreases the insoluble Aβ1–42 level in hippocampus and protects the integrity of the blood–brain barrier in AD rats

Cited by 121 publications

References 62 publications

Targeting neuroinflammation in Alzheimer’s disease: evidence for NSAIDs and novel therapeutics

Targeting neuroinflammation in Alzheimer’s disease: evidence for NSAIDs and novel therapeutics

The Immunomodulatory Effects of Plant Extracts and Plant Secondary Metabolites on Chronic Neuroinflammation and Cognitive Aging: A Mechanistic and Empirical Review

Antioxidants and Dementia Risk: Consideration through a Cerebrovascular Perspective

Contact Info

Product

Resources

About